• Duración:
    16 semanas
  • Dedicación:
    10–12 horas por semana
  • Precio:

    GRATIS
    Agregar un Certificado Verificado por $49 USD

  • Institución
  • Tema:
  • Nivel:
    Intermediate
  • Idioma:
    English
  • Transcripción de video:
    English
  • Tipo de curso:
    A tu ritmo

Prerrequisitos

None

Sobre este curso

Omitir Sobre este curso

This course focuses on early-stage biotechnology companies, with particular emphasis on understanding the underlying science, technology, and disease targets—together with the application of novel business structures and financing methods—to facilitate drug discovery, clinical development, and greater patient access to new therapies.

Current research is enhancing our understanding of the genetic, molecular, and cellular bases of many human diseases, and is leading to many new types of biotherapeutics that we will cover in this course, including recombinant therapeutic proteins; monoclonal antibodies and antibody drug conjugates; cancer immunotherapies, replacement cells and genetically engineered cells; and nucleic acid and gene therapies. Translating these discoveries into drugs and diagnostics increasingly requires the establishment of for-profit companies, but funding for early-stage development of novel therapies is becoming scarcer, especially for therapeutics for “rare” diseases that affect small populations. The dearth of funding for early-stage biotherapeutics companies in the so-called “Valley of Death” can be attributed to several factors, but a common thread is increasing financial risks in the biopharma industry and greater uncertainty surrounding the scientific, medical, economic, political, and academic environments within the biomedical ecosystem. Increasing risk and uncertainty inevitably leads to an outflow of capital as investors and other stakeholders seek more attractive opportunities in other industries.

By applying financial techniques such as portfolio theory, securitization, and derivative securities to biomedical contexts, more efficient business and funding structures can be developed to reduce financial risks, lower the cost of capital, and bring more life-saving therapies to patients faster. Thus this course will also cover basic financial analysis for the life-sciences professional; the historical financial risks and returns of the biotech and pharmaceutical industries; the evaluation of the science and business potential as well as the mechanics of financing biotech startups; capital budgeting for biopharmaceutical companies; and applications of financial engineering in drug royalty investment companies, biomedical megafunds, drug approval swaps, and life sciences investment banking.

Lo que aprenderás

Omitir Lo que aprenderás
  • Basic financial analysis for the life-sciences professional
  • The historical financial risks and returns of the biopharma industry
  • Capital budgeting for pharmaceutical companies
  • Drug development and clinical trials
  • The mechanics of biotech startup financing
  • Biomedical megafunds and drug royalty investment companies
  • Healthcare analytics and machine learning
  • Pricing, value, and ethics

Plan de estudios

Omitir Plan de estudios

* Week 0:** Intro to the Science of Biotech and Healthcare Finance

  • Week 1: Therapeutic Recombinant Proteins; Present Value

* Week 2:** AAV Vectors & In Vivo Gene Therapy; Capital Budgeting

* Week 3:** Ex Vivo Gene Therapy; Stocks and Bonds

* Week 4:** Nucleic Acid Therapies; The CAPM & Diversification

* Week 5:** Gene Editing; Options

* Week 6:** Clinical Trials

  • Week 7: Antibody Generation; Venture Capital & New Business Models

* Week 8:** Monoclonal Antibodies; Securitization

* Week 9:** Cancer Immunotherapeutic; Healthcare Analytics

* Week 10:** New Cell Therapies; Pricing, Value & Ethics

Conoce a tus instructores

Andrew W. Lo
Professor,
MIT Sloan School of Management
Harvey F. Lodish
Professor of Biology and Professor of Biological Engineering, M.I.T. Founding Member, Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology
Zied Ben Chaouch
TA and PhD Student, Laboratory for Financial Engineering
Massachusetts Institute of Technology

Obtén un Certificado Verificado para destacar los conocimientos y las habilidades que adquieras
$49 USD

Ver un modelo de certificado de edX en PDF
  • Oficial y verificado

    Obtén un certificado con la firma del instructor y el logotipo de la institución para demostrar tus logros y aumentar las posibilidades de conseguir trabajo

  • Fácil de compartir

    Agrega el certificado a tu currículum o publícalo directamente en LinkedIn

  • Incentivo comprobado

    El certificado te da un motivo más para completar el curso

  • Apoya nuestra labor

    edX, una organización sin fines de lucro, se sustenta con los certificados verificados para financiar la educación gratuita para todo el mundo

¿Quién puede hacer este curso?

Lamentablemente, las personas de uno o más de los siguientes países o regiones no podrán registrarse para este curso: Irán, Cuba y la región de Crimea en Ucrania. Si bien edX consiguió licencias de la Oficina de Control de Activos Extranjeros de los EE. UU. (U.S. Office of Foreign Assets Control, OFAC) para ofrecer nuestros cursos a personas en estos países y regiones, las licencias que hemos recibido no son lo suficientemente amplias como para permitirnos dictar este curso en todas las ubicaciones. edX lamenta profundamente que las sanciones estadounidenses impidan que ofrezcamos todos nuestros cursos a cualquier persona, sin importar dónde viva.